(EMAILWIRE.COM, April 25, 2019 ) The miRNA sequencing and assays market is projected to reach USD 343 million by 2024 from USD 182 million in 2018, at a CAGR of 11.2%. Growth in this market is driven by factors such as the advantages of miRNA sequencing over other technologies, increasing research funding for genomics, and the decreasing cost of sequencing.

North America is expected to account for the largest market share during the forecast period.

North America held the largest share of the market in 2018 and this trend is expected to continue during the forecast period. Factors such as increasing investments in the development of sequencing, growing research in the fields of genomics and RNA biology, and the rising demand for economical, high-throughput techniques for miRNA analysis are driving the growth of the miRNA sequencing & assays market in this region.

The major miRNA sequencing and assays vendors include Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Germany), Takara Bio (Japan), NEB (UK), and 5 others.

Recent Developments:

-In 2018, Illumina partnered with Thermo Fisher to provide Ampliseq technology solutions to its customers.
-In 2017, Takara Bio acquired WaferGen to augment and expand Takara Bio’s worldwide commercial offerings in transcriptomics and create new market opportunities in other areas of genomics.
-In 2016, PerkinElmer acquired Bioo Scientific, which provides consumables solutions for life science research, and food and animal-feed safety testing.